Shareholder Vote

Common Shares, Without Par Value   ABT       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549       FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   April 29, 2022 Date of Report (Date of earliest event reported)     ABBOTT LABORATORIES (Exact name of registrant as specified in charter)       Illinois   1-2189   36-0698440 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification  No.)       100 Abbott Park Road Abbott Park , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 224 ) 667-6100   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities Registered Pursuant to Section 12(b) of the Act:   Title of Each Class Trading Symbol(s) Name of Each Exchange on  Which Registered Common Shares, Without Par Value ABT New York Stock Exchange Chicago Stock Exchange, Inc.   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨          I tem 5.07 — Submission of Matters to a Vote of Security Holders.   Abbott held its Annual Meeting of Shareholders on April 29, 2022. The following is a summary of the matters voted on at that meeting.   (1) The shareholders elected Abbott’s entire Board of Directors. The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number of shares withheld, and the number of broker non-votes, with respect to each of these persons, were as follows:   Name   Votes For     Votes Withheld     Broker Non-Votes   Robert J. Alpern, M.D.     1,300,318,741       50,116,071       186,229,036   Sally E. Blount, Ph.D.     1,322,633,909       27,800,903       186,229,036   Robert B. Ford     1,265,246,918       85,187,894       186,229,036   Paola Gonzalez     1,344,735,483       5,699,329       186,229,036   Michelle A. Kumbier     1,328,758,586       21,676,226       186,229,036   Darren W. McDew     1,333,987,306       16,447,506       186,229,036   Nancy McKinstry     1,037,568,700       312,866,112       186,229,036   William A. Osborn     1,243,331,162       107,103,650       186,229,036   Michael F. Roman     1,321,772,019       28,662,793       186,229,036   Daniel J. Starks     1,343,614,722       6,820,090       186,229,036   John G. Stratton     1,247,765,004       102,669,808       186,229,036   Glenn F. Tilton     1,288,825,816       61,608,996       186,229,036     (2) The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors. The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows:   For   Against   Abstain   Broker Non-Votes 1,523,487,443   9,931,288   3,245,117   0     (3) The shareholders approved the compensation of Abbott’s named executive officers listed in the proxy statement for the Annual Meeting, with 91.27 percent of the votes cast voting “For” the proposal. The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:   For   Against   Abstain   Broker Non-Votes 1,232,623,436   110,410,371   7,401,005   186,229,036         (4) The shareholders rejected a shareholder proposal to lower the ownership threshold for calling special meetings of shareholders, with 47.15 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:   For   Against   Abstain   Broker Non-Votes 636,741,987   707,817,833   5,874,992   186,229,036   (5) The shareholders rejected a shareholder proposal requesting that Abbott’s Board of Directors adopt a policy that the Board Chairman be an independent director, with 27.75 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:   For   Against   Abstain   Broker Non-Votes 374,824,445   971,036,526   4,573,841   186,229,036   (6) The shareholders rejected a shareholder proposal that Abbott’s Board of Directors adopt a policy on Rule 10b5-1 plans with certain restrictions and disclosure requirements, with 48.76 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:   For   Against   Abstain   Broker Non-Votes 658,539,820   684,198,068   7,696,924   186,229,036                 (7) The shareholders rejected a shareholder proposal that Abbott’s Board of Directors prepare a report, to be updated annually, disclosing Abbott’s lobbying policies, procedures, and expenditures, with 34.52 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:     For   Against   Abstain   Broker Non-Votes 466,227,363   877,646,614   6,560,835   186,229,036                 (8) The shareholders rejected a shareholder proposal that Abbott’s Board of Directors prepare a report on the public health costs and financial market impacts of Abbott’s standards and programs regarding antimicrobial resistance, with 11.51 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:   For   Against   Abstain   Broker Non-Votes 155,376,554   1,187,364,353   7,693,905   186,229,036         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     ABBOTT LABORATORIES   Date: May 2, 2022 By: /s/ Robert E. Funck, Jr.     Robert E. Funck, Jr.     Executive Vice President, Finance and Chief Financial Officer